Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Assets (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Non-Current Assets for 16 consecutive years, with $13.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets rose 38.54% year-over-year to $13.5 million, compared with a TTM value of $47.5 million through Sep 2025, up 14.37%, and an annual FY2024 reading of $11.6 million, up 10.93% over the prior year.
  • Non-Current Assets was $13.5 million for Q3 2025 at China Pharma Holdings, up from $11.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $15.0 million in Q1 2021 and bottomed at $9.5 million in Q3 2023.
  • Average Non-Current Assets over 5 years is $11.8 million, with a median of $11.4 million recorded in 2025.
  • The sharpest move saw Non-Current Assets decreased 24.53% in 2022, then surged 38.54% in 2025.
  • Year by year, Non-Current Assets stood at $13.6 million in 2021, then fell by 12.81% to $11.8 million in 2022, then dropped by 11.4% to $10.5 million in 2023, then increased by 10.93% to $11.6 million in 2024, then grew by 16.0% to $13.5 million in 2025.
  • Business Quant data shows Non-Current Assets for CPHI at $13.5 million in Q3 2025, $11.1 million in Q2 2025, and $11.4 million in Q1 2025.